Adding to the good news, Hazan expects annual growth contribution from new products to accelerate thanks to the release of its da Vinci Sp, Ion ﬂex diagnostic platform, IRIS augmented reality and several new advanced stage instruments in 2020 and 2021.“While not very material quite yet, we expect this new segment to grow faster than the corporate average, be accretive to margins and earnings, and to diversify the Varian portfolio into new oncology channels and additional recurring revenue.